Polysaccharide derivatives and dosage forms
View Patent ↗Polysaccharide derivatives having a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both are useful for preparing dosage forms, particularly for preparing compressed sustained-release dosage forms: A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40 and an outlet diameter of about 50 mm, or B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
1. A polysaccharide derivative which is a particulate cellulose ether or cellulose ester having a median Equivalent Projected Circle Diameter (EQPC) of at least 30 micrometers and less than 140 micrometers and a particle size and shape distribution such that
no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
2. The polysaccharide derivative of claim 1 having a particle size and shape distribution such that non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec. through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm.
3. The polysaccharide derivative of claim 1 having a particle size and shape distribution such that i) no more than 30 volume percent of the particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 30 volume percent of the particles are fibrous particles, and the sum of the fine particles and fibrous particles does not exceed 40 volume percent.
4. The polysaccharide derivative of claim 1 having a median Equivalent Projected Circle Diameter (EQPC) of no more than 130 micrometers.
5. The polysaccharide derivative of claim 1 having an untapped bulk density of more than 0.35 kg/m 3 .
6. A dosage form produced from
a) one or more polysaccharide derivatives of claim 1 , b) one or more active ingredients, and c) one or more optional adjuvants.
7. The dosage form of claim 6 being a compressed dosage form wherein the polysaccharide derivative forms at least a portion of the matrix of the dosage form.
8. The dosage form of claim 6 wherein the polysaccharide derivative forms at least a portion of the coating of the dosage form.
9. The dosage form of claim 6 being a sustained-release dosage form.
10. A process for preparing a dosage form comprising the step of
I.) blending one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants, and
II.) compressing the blend to a dosage form,
wherein said one or more polysaccharide derivatives have a median Equivalent Projected Circle Diameter (EQPC) of less than 140 micrometers and a particle size and shape distribution meeting condition A or B or both:
A. non-compacted polysaccharide derivative particles have a flowability of at least 45 g/sec through a vertically inverted cone having a vertex angle of about 40° and an outlet diameter of about 50 mm, or
B. i) no more than 40 volume percent of the polysaccharide derivative particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 40 volume percent of the polysaccharide derivative particles are fibrous particles, and the sum of the fine particles and the fibrous particles does not exceed 50 volume percent.
11. The process of claim 10 wherein in step I.) one or more polysaccharide derivatives, one or more active ingredients, and one or more optional adjuvants are blended in the absence of a substantial amount of added solvent or heat.
12. The polysaccharide derivative of claim 2
having a particle size and shape distribution such that i) no more than 30 volume percent of the particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 30 volume percent of the particles are fibrous particles, and the sum of the fine particles and fibrous particles does not exceed 40 volume percent,
having a median Equivalent Projected Circle Diameter (EQPC) of no more than 130 micrometers, and
having an untapped bulk density of more than 0.35 kg/m 3 .
13. The polysaccharide derivative of claim 12 being a cellulose ether or cellulose ester selected from the group consisting of methylcellulose, methyl hydroxyethyl cellulose, methyl hydroxypropyl cellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose and combinations thereof.
14. The dosage form of claim 6 wherein the polysaccharide derivative has
a particle size and shape distribution such that i) no more than 30 volume percent of the particles are fine particles having a particle length LEFI of less than 40 micrometers and ii) no more than 30 volume percent of the particles are fibrous particles, and the sum of the fine particles and fibrous particles does not exceed 40 volume percent, and
a median Equivalent Projected Circle Diameter (EQPC) of no more than 130 micrometers.
15. The polysaccharide derivative of claim 1 being a methyl hydroxypropyl cellulose.
16. The polysaccharide derivative of claim 13 being a methyl hydroxypropyl cellulose.